Download Therapeutic Strategies To Overcome Alk Resistance In Cancer Book PDF

Download full Therapeutic Strategies To Overcome Alk Resistance In Cancer books PDF, EPUB, Tuebl, Textbook, Mobi or read online Therapeutic Strategies To Overcome Alk Resistance In Cancer anytime and anywhere on any device. Get free access to the library by create an account, fast download and ads free. We cannot guarantee that every book is in the library.

Therapeutic Strategies to Overcome ALK Resistance in Cancer

Therapeutic Strategies to Overcome ALK Resistance in Cancer
  • Author : Luc Friboulet
  • Publisher :Unknown
  • Release Date :2021-01-18
  • Total pages :216
  • ISBN : 9780128217795
GET BOOK HERE

Summary : Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field. This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment. Explains the biology of ALK RTK, focusing on its tissue expression, structure and functionality Presents an overview of current treatments and the benefits of ALK TKI in lung and other cancer types, such as ALCL, neuroblastoma and inflammatory myofibroblastic tumor Encompasses information on systemic treatments other than TKI, including chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC

Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners

Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners
  • Author : Marianne Davies,Beth Eaby-Sandy
  • Publisher :Unknown
  • Release Date :2019-07-16
  • Total pages :120
  • ISBN : 9783030165505
GET BOOK HERE

Summary : This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP’s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP’s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.

Resistance to Tyrosine Kinase Inhibitors

Resistance to Tyrosine Kinase Inhibitors
  • Author : Daniele Focosi
  • Publisher :Unknown
  • Release Date :2016-11-07
  • Total pages :188
  • ISBN : 9783319460918
GET BOOK HERE

Summary : The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.

Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies

Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies
  • Author : Chi Hin Cho,Tao Hu
  • Publisher :Unknown
  • Release Date :2020-05-24
  • Total pages :240
  • ISBN : 9780128199381
GET BOOK HERE

Summary : Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, Volume Eight, summarizes the molecular mechanisms of drug resistance in colorectal cancer, along with the most up-to-date therapeutic strategies available. The book discusses reasons why colorectal tumors become refractory during the progression of the disease, but also explains how drug resistance occurs during chemotherapy. In addition, users will find the current therapeutic strategies used by clinicians in their practice in treating colorectal cancer. The combination of conventional anticancer drugs with chemotherapy-sensitizing agents plays a pivotal role in improving the outcome of colorectal cancer patients, in particular those with drug-resistant cancer cells. From a clinical point-of-view, the content of this book provides clinicians with updated therapeutic strategies for a better choice of drugs for drug-resistant colorectal cancer patients. It will be a valuable source for cancer researchers, oncologists and several members of biomedical field who are dedicated to better treat patients with colorectal cancer. Presents a systemic summary of molecular mechanisms for a quick and in-depth understanding Updates current trends in the field with pioneering information on drug resistance Encompasses both basic and clinical approaches for a better understanding of unsolved problems from a holistic point-of-view

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance
  • Author : Andrew Freywald,Franco Vizeacoumar
  • Publisher :Unknown
  • Release Date :2020-12-04
  • Total pages :308
  • ISBN : 9780128213117
GET BOOK HERE

Summary : Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance. Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges. Provides the most updated knowledge on the mechanisms of cancer drug resistance and the emerging therapeutic approaches reviewed by experts in the field Brings detailed analyses of most important recently reported developments related to drug resistance and their relevance to overcoming it in cancer patients Discusses in-depth molecular mechanisms and novel concepts of cancer resistance to conventional and advanced therapies

Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance
  • Author : Goli Samimi,Christina Annunziata
  • Publisher :Unknown
  • Release Date :2020-11-06
  • Total pages :188
  • ISBN : 9780128198414
GET BOOK HERE

Summary : Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

Progressive Neuroblastoma

Progressive Neuroblastoma
  • Author : H. Christiansen,N.M. Christiansen
  • Publisher :Unknown
  • Release Date :2015-09-28
  • Total pages :192
  • ISBN : 9783318054972
GET BOOK HERE

Summary : Neuroblastoma is a tumor derived from the sympathetic nervous system. It is the most common extracranial solid tumor occurring in children and exhibits a marked variability in outcome when the disease is categorized by clinical (e.g. age or stage) and biologic characteristics. This book gives an introduction into the clinical features of progressive neuroblastoma and focuses on molecular-targeted therapies and immunotherapies of this disease. It has become increasingly clear that MYCN (v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog) holds a key position in neuroblastic transformation and gene expression in normal and transformed cells. In the 14 chapters important topics such as genomic alterations in neuroblastoma and strategies for indirect molecular targeting of MYCN are discussed. Two chapters, for example, review apoptotic pathways and proapoptotic molecular targets in neuroblastoma, one focusing on the p53 pathway and the extrinsic and intrinsic pathways of apoptosis. Other chapters cover topics related to immunology in neuroblastoma, such as immune regulation in neuroblastoma, immunotherapy related to passive and active vaccination approaches and additional immunotherapy in the treatment of progressive disease. This volume will be essential reading for all clinicians and basic researchers who are involved in delivering health care to patients with progressive neuroblastoma.

New Therapeutic Strategies in Lung Cancers

New Therapeutic Strategies in Lung Cancers
  • Author : Solange Peters,Benjamin Besse
  • Publisher :Unknown
  • Release Date :2014-10-01
  • Total pages :255
  • ISBN : 9783319060620
GET BOOK HERE

Summary : This book provides an up-to-date review of current management techniques for Non-Small Cell Lung Cancer. It addresses all of the latest issues that have been raised by the discovery of oncogenic drivers and the improvement of diagnosis and therapeutic methods, including new radiotherapy techniques and anticancer strategies like immunotherapy. New strategies for patients with molecular alterations and the management of particular types of cases are also highlighted. Written by recognized experts in their field, the book represents a unique and valuable resource in the field of lung cancer, both for those currently in training and for those already in clinical or research practice.

Successes and Limitations of Targeted Cancer Therapy

Successes and Limitations of Targeted Cancer Therapy
  • Author : S. Peters,R.A. Stahel
  • Publisher :Unknown
  • Release Date :2014-02-19
  • Total pages :124
  • ISBN : 9783318025422
GET BOOK HERE

Summary : The treatment of patients with advanced malignancies has undergone remarkable change in the last few years. While in the past decisions about systemic therapy were largely based on the performance status of a patient, oncologists today also take into account the pathological and molecular characteristics of the patient’s tumor. Targeting specific molecular pathways important for tumorigenesis has become the preferred way of treatment for many types of malignancies. With these advances come new challenges including the optimization of therapy, recognizing and dealing with side effects and, importantly, the development of resistance. This book provides an up-to-date overview of the advances and limitations of targeted therapy for several tumor entities including breast cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, melanoma, ovarian cancer and renal cell carcinoma. Written by over a dozen internationally renowned scientists, the book is suitable for advanced students, postdoctoral researchers, scientists and clinicians who wish to update their knowledge of the latest approaches to targeted cancer therapies.

Targeted Therapies in Oncology, Second Edition

Targeted Therapies in Oncology, Second Edition
  • Author : Giuseppe Giaccone,Jean-Charles Soria
  • Publisher :Unknown
  • Release Date :2013-10-21
  • Total pages :498
  • ISBN : 9781842145456
GET BOOK HERE

Summary : Since the last edition of this book, major advances have been made in our understanding of key pathways that control tumor progression. This has led to the development of new anticancer agents that have the ability to block the activity of proteins involved in neoplastic cell development and proliferation. Targeted Therapies in Oncology, Second Edition provides a concise timely panorama of existing targeted therapies and progress into future anticancer treatments. These therapies notably include: Targeted agents of immune checkpoints Signal-transduction inhibitors Antiangiogenic agents Vascular-disrupting agents Apoptosis modulators Stem cell inhibitors Tumor profiling for drug development The book emphasizes the biology behind this new class of drugs as well as the clinical achievements obtained. The contributors to this volume stand at the cutting edge of cancer research and treatment around the world.

Lung Cancer

Lung Cancer
  • Author : Alba Fabiola Costa Torres
  • Publisher :Unknown
  • Release Date :2018-10-31
  • Total pages :204
  • ISBN : 9781789843491
GET BOOK HERE

Summary : Among the deadliest type of cancers, lung cancer faces several challenges in diagnosis and treatment: late diagnosis and misdiagnosis, inadequate tumor sampling, and resistance development to current therapies, among others. Together with advances in the understanding of molecular features, factors, and mechanisms involved in initiation and tumor progression, important improvements have occurred in diagnostics and therapeutics in the shape of advances in molecular genotyping, procedures for sampling, new potential, and less invasive sources of samples for the diagnosis and development of new targeted therapies. The aim of this book is to provide an exciting read on strategies in the diagnosis and therapy of lung cancer.

Current Applications for Overcoming Resistance to Targeted Therapies

Current Applications for Overcoming Resistance to Targeted Therapies
  • Author : Myron R. Szewczuk,Bessi Qorri,Manpreet Sambi
  • Publisher :Unknown
  • Release Date :2019-07-15
  • Total pages :320
  • ISBN : 9783030214777
GET BOOK HERE

Summary : Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.

Lung Cancer

Lung Cancer
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2012-05-18
  • Total pages :572
  • ISBN : 9781617050978
GET BOOK HERE

Summary : With contributions from internationally recognized experts, Lung Cancer details the current management of lung cancer and reviews new therapies in development for lung cancer, with an emphasis on therapeutic exploitation of the heterogeneous nature of lung tumors at the molecular level. Coverage includes discussion of multiple new agents that have been shown to impact overall survival as well as articles covering molecular biology of lung cancer, chemotherapy regimens for lung cancer, the emergence of maintenance therapy, the complexity of radiotherapy in the chest, the impact of adjuvant chemotherapy for resected non-small cell lung cancer, surgical considerations for early-stage lung cancer, and more. This book is a valuable tool for clinicians, nurses, researchers, medical students, residents, and fellows. Emerging Cancer Therapeutics features: Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics Issues edited by an authority in specific subject area Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience Emphasizes multidisciplinary approaches to research and practice

Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy
  • Author : Benjamin Bonavida
  • Publisher :Unknown
  • Release Date :2013-07-04
  • Total pages :260
  • ISBN : 9781461470700
GET BOOK HERE

Summary : ​​​​​This volume gives the latest developments in on the mechanisms of cancer cell resistance to apoptotic stimuli, which eventually result in cancer progression and metastasis. One of the main challenges in cancer research is to develop new therapies to combat resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance to cytotoxic drug-induced apoptosis. These mechanisms should reveal gene products that directly regulate resistance in order to develop new drugs that target these resistance factors and such new drugs may either be selective or common to various cancers. If successful, new drugs may not be toxic and may be used effectively in combination with subtoxic conventional drugs to achieve synergy and to reverse tumor cell resistance. The research developments presented in this book can be translated to produce better clinical responses to resistant tumors.

Neuroblastoma

Neuroblastoma
  • Author : Chandrika Gowda
  • Publisher :Unknown
  • Release Date :2017-10-25
  • Total pages :168
  • ISBN : 9789535135838
GET BOOK HERE

Summary : Neuroblastoma (NBL) is the most common extracranial solid tumor of childhood, with about 700 new cases of neuroblastoma seen each year in the United States. The 5-year survival rate for children with high-risk NBL is only 50-60%, and this survival rate has not improved over the last 10 years. High-risk patients receive multimodality treatment, including chemotherapy, surgery, radiation therapy, biologic therapy and immunotherapy, all of which are associated with significant morbidity. Recent years have seen many advances in treatment of neuroblastoma, including therapeutic MIBG, immunotherapy, and personalized targeted therapy based on the genetic alterations seen in the tumor. The primary objective of this book is to provide the readers with a comprehensive review of neuroblastoma, from clinical aspects and the currently available treatment to recent advancements and future directions in the field of NBL treatment. The topics and chapters have been compiled keeping in mind a diverse group of readers in different areas of specialty such as pediatric oncology, surgery, radiation oncology, and immunology, as well as physician scientists and basic researchers working in the field of neuroblastoma.

Central Nervous System Metastases

Central Nervous System Metastases
  • Author : Manmeet Ahluwalia,Philippe Metellus,Riccardo Soffietti
  • Publisher :Unknown
  • Release Date :2019-11-05
  • Total pages :421
  • ISBN : 9783030234171
GET BOOK HERE

Summary : This book provides a comprehensive overview of brain metastases, from the molecular biology aspects to therapeutic management and perspectives. Due to the increasing incidence of these tumors and the urgent need to effectively control brain metastatic diseases in these patients, new therapeutic strategies have emerged in recent years. The volume discusses all these innovative approaches combined with new surgical techniques (fluorescence, functional mapping, integrated navigation), novel radiation therapy techniques (stereotactic radiosurgery) and new systemic treatment approaches such as targeted- and immunotherapy. These combination strategies represent a new therapeutic model in brain metastatic patients in which each medical practitioner (neurosurgeon, neurologist, medical oncologist, radiation oncologist) plays a pivotal role in defining the optimal treatment in a multidisciplinary approach. Written by recognized experts in the field, this book is a valuable tool for neurosurgeons, neuro-oncologists, neuroradiologists, medical oncologists, radiation oncologists, cognitive therapists, basic scientists and students working in the area of brain tumors.

Drug Resistance in Cancer Cells

Drug Resistance in Cancer Cells
  • Author : Kapil Mehta,Zahid H. Siddik
  • Publisher :Unknown
  • Release Date :2009-06-12
  • Total pages :363
  • ISBN : 0387894454
GET BOOK HERE

Summary : It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt – in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger de?nition – multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies – its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original de?nition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by many factors.

Cancer Evolution

Cancer Evolution
  • Author : Charles Swanton
  • Publisher :Unknown
  • Release Date :2017
  • Total pages :350
  • ISBN : 1621821439
GET BOOK HERE

Summary : Tumor progression is driven by mutations that confer growth advantages to different subpopulations of cancer cells. As a tumor grows, these subpopulations expand, accumulate new mutations, and are subjected to selective pressures from the environment, including anticancer interventions. This process, termed clonal evolution, can lead to the emergence of therapy-resistant tumors and poses a major challenge for cancer eradication efforts. Written and edited by experts in the field, this collection from Cold Spring Harbor Perspectives in Medicine examines cancer progression as an evolutionary process and explores how this way of looking at cancer may lead to more effective strategies for managing and treating it. The contributors review efforts to characterize the subclonal architecture and dynamics of tumors, understand the roles of chromosomal instability, driver mutations, and mutation order, and determine how cancer cells respond to selective pressures imposed by anticancer agents, immune cells, and other components of the tumor microenvironment. They compare cancer evolution to organismal evolution and describe how ecological theories and mathematical models are being used to understand the complex dynamics between a tumor and its microenvironment during cancer progression. The authors also discuss improved methods to monitor tumor evolution (e.g., liquid biopsies) and the development of more effective strategies for managing and treating cancers (e.g., immunotherapies). This volume will therefore serve as a vital reference for all cancer biologists as well as anyone seeking to improve clinical outcomes for patients with cancer.

Dynamics of Cancer

Dynamics of Cancer
  • Author : Dominik Wodarz,Natalia L Komarova
  • Publisher :Unknown
  • Release Date :2014-04-24
  • Total pages :532
  • ISBN : 9789814566384
GET BOOK HERE

Summary : The book aims to provide an introduction to mathematical models that describe the dynamics of tumor growth and the evolution of tumor cells. It can be used as a textbook for advanced undergraduate or graduate courses, and also serves as a reference book for researchers. The book has a strong evolutionary component and reflects the viewpoint that cancer can be understood rationally through a combination of mathematical and biological tools. It can be used both by mathematicians and biologists. Mathematically, the book starts with relatively simple ordinary differential equation models, and subsequently explores more complex stochastic and spatial models. Biologically, the book starts with explorations of the basic dynamics of tumor growth, including competitive interactions among cells, and subsequently moves on to the evolutionary dynamics of cancer cells, including scenarios of cancer initiation, progression, and treatment. The book finishes with a discussion of advanced topics, which describe how some of the mathematical concepts can be used to gain insights into a variety of questions, such as epigenetics, telomeres, gene therapy, and social interactions of cancer cells. Contents:Teaching GuideCancer and Somatic EvolutionMathematical Modeling of TumorigenesisBasic Growth Dynamics and Deterministic Models:Single Species GrowthTwo-Species Competition DynamicsCompetition Between Genetically Stable and Unstable CellsChromosomal Instability and Tumor GrowthAngiogenesis Inhibitors, Promoters, and Spatial GrowthEvolutionary Dynamics and Stochastic Models:Evolutionary Dynamics of Tumor Initiation Through Oncogenes: The Gain-of-Function ModelEvolutionary Dynamics of Tumor Initiation Through Tumor-Suppressor Genes: The Loss-of-Function Model and Stochastic TunnelingMicrosatellite and Chromosomal Instability in Sporadic and Familial Colorectal CancersEvolutionary Dynamics in Hierarchical PopulationsSpatial Evolutionary Dynamics of Tumor InitiationComplex Tumor Dynamics in SpaceStochastic Modeling of Cellular Growth, Treatment, and Resistance GenerationEvolutionary Dynamics of Drug Resistance in Chronic Myeloid LeukemiaAdvanced Topics:Evolutionary Dynamics of Stem-Cell Driven Tumor GrowthTumor Growth Kinetics and Disease ProgressionEpigenetic Changes and the Rate of DNA MethylationTelomeres and Cancer ProtectionGene Therapy and Oncolytic Virus TherapyImmune Responses, Tumor Growth, and TherapiesTowards Higher Complexities: Social Interactions Readership: Researchers in mathematical biology, mathematical modeling, biology, mathematical oncology. Keywords:Mathematical Oncology;Dynamics;Evolution;Evolutionary Dynamics;Cancer;Mathematical Models;Somatic Evolution;TeachingKey Features:Both a reference book for the topic, and provides material for undergraduate and graduate coursesTries to bridge the divide between mathematicians and biologists, which is also reflected in the backgrounds of the two authorsShows how mathematical concepts can be translated into experimentally and clinically useful insightsRooted in evolutionary biology, the book handles this very complex phenomenon in an intuitive and mathematically elegant wayContains problems and research projects for each topic10 pages of figures in color

Small Molecules in Oncology

Small Molecules in Oncology
  • Author : Uwe M. Martens
  • Publisher :Unknown
  • Release Date :2010-01-14
  • Total pages :238
  • ISBN : 3642012221
GET BOOK HERE

Summary : Extensive research into the molecular mechanisms of cancer disease has heralded a new age of targeted therapy. In malignant cells, key proteins that are crucial to tumor growth and survival are now being targeted directly with rationally designed inhibitors. Apart from monoclonal antibodies, small molecule therapeutics such as oncogenic protein kinase inhibitors are attracting a vast amount of investigational attention. This textbook, written by acknowledged experts, provides a broad overview of the small molecules currently used for the treatment of malignant diseases and discusses interesting novel compounds that are in the process of clinical development to combat cancer.

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2018-11-21
  • Total pages :292
  • ISBN : 9780128127384
GET BOOK HERE

Summary : Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment